The LUNAR trial is intended for patients who have recently been diagnosed with progression of non-small cell lung cancer (NSCLC) during or after platinum based therapy. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. Novocure, the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial [ LUNAR Centers ]. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel ... | October 16, 2020 LUNAR is a pivotal, phase III trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields), generated by a medical device, the NovoTTF-100L System in … This website intends to use cookies to improve the site and your experience. ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy.The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in … Novocure’s INNOVATE trial examined Tumor Treating Fields in combination with standard of care chemotherapy in patients with recurrent platinum-resistant ovarian cancer. Tumor Treating Fields (TTFields) therapy is not approved for the treatment of NSCLC by the U.S. Food and Drug Administration. “We are excited about the potential of TTFields for the treatment of advanced NSCLC, and we are pleased to start this pivotal trial.”. Novocure is due to issue an interim analysis of a phase three pivotal LUNAR trial in non-small-cell lung cancer. The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in combination with immune checkpoint inhibitors or docetaxel – a taxane chemotherapy – two of the current standard of care treatments. Specifically, it was being explored in patients who progressed during or … Patient images reflect the health status of the patients at the time each photo or video was taken. Please click here to access it. It also plans to issue an interim analysis of a phase three pivotal PANOVA-3 trial in locally advanced pancreatic cancer as well as an interim analysis of a phase three pivotal INNOVATE-3 trial in recurrent ovarian cancer. In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. In addition, the trial design was informed by Novocure’s phase 2 pilot EF-15 trial1, which tested TTFields at 150 kHz in combination with pemetrexed chemotherapy in 42 patients with advanced second- or subsequent-line NSCLC. We are developing a profoundly different approach to cancer therapy that has the potential to improve the lives of people affected by a range of solid tumor cancers.”. At 10%-30% peak market penetration, 0.5 billion to 1.5 billion can be added to NovoCure revenue. The LUNAR trial design was based on preclinical findings that suggest TTFields may act synergistically with certain taxanes and enhance the efficacy of immune checkpoint inhibitors. Final data from phase 3 LUNAR trial in NSCLC, from phase 3 PANOVA-3 trial … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … ... Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer (2021) Novocure in light of industry experience and perception of historical trends, current conditions, expected future developments and other appropriate factors. The safety and effectiveness of TTFields therapy for NSCLC has not been established. http://www.businesswire.com/news/home/20170215005187/en/, Novocure Vulnerability Disclosure Process. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov. If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. In addition, the trial will test non-inferiority in overall survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone. Novocure also plans to highlight key clinical and product development … The NovoTTF-100L System delivers Tumor Treating Fields (TTFields) to the cancer in the chest. Professor Yoram Palti founded Novocure in 2000. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields … The science of Tumor Treating Fields extends beyond glioblastoma. “We designed this trial to test TTFields with two of the currently available standard of care treatments for advanced NSCLC following failure of platinum-based therapy, opening the trial to more patients with this disease,” said Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development. Company Participants. We completed phase 2 pilot trials in pancreatic cancer and ovarian cancer, and shared the topline results at our research and development day in … For more information on the trial design, visit ClinicalTrials.gov. Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019. NovoCure (NASDAQ:NVCR) Q2 ... tumor treating fields and anti-PD-1 therapies as a second-line treatment for stage IV non-small cell lung cancer in our Lunar trial… Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Ashley Cordova - Senior Vice … Novocure to present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. “The start of LUNAR, our second ongoing phase 3 trial beyond glioblastoma, further demonstrates our commitment to testing TTFields across a variety of solid tumor cancers and bringing our therapy to patients who may benefit from it,” said Novocure CEO Asaf Danziger. 1 Pless M. et al., A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2023) ... Novocure will host a conference call and webcast to discuss fourth quarter and … The international trial is planned to include 512 patients with stage IIIB and IV NSCLC of all histologies after failing platinum-based therapy. Following the study, Novocure announced that it was testing the combination of Tumor Treating Fields with immune checkpoint inhibitors in its Phase III LUNAR trial in patients with stage 4 NSCLC. Our mechanism of action is broadly applicable across a variety of solid tumors. During her seventeen years with Novocure, she and the preclinical team have researched the effects of TTFields on a variety of solid tumor cancer cell lines and laid the foundation for Novocure’s expansion into additional clinical trials. “We believe that treatment with TTFields is bigger than one cancer type. The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. Novocure reported financial results for the quarter ended June 30, 2020, and provided a company update. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … The incidence of NSCLC in the U.S. is approximately 185,000 new cases annually. We have since accomplished many significant milestones. By continuing to browse the site you are agreeing to accept our use of cookies. ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020.Novocure plans to discuss these results with investors at the 39 th Annual J.P. Morgan Virtual Healthcare Conference. The Private Securities Litigation Reform Act of 1995 permits this discussion. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. Non-small cell lung cancer (NSCLC) accounts for approximately 85 percent of all lung cancers. This clinical trial is evaluating the safety and efficacy of the NovoTTF-100L System for use in NSCLC, when added to either an immune checkpoint inhibitor or docetaxel which are normally given to patients in this condition. Therefore, you should not rely on any such factors or forward-looking statements. Novocure today reported fourth quarter and full year 2019 financial results and provided a company update. Notably, the EF-15 trial also included patients with squamous histology (n=7, 17 percent), who typically do not respond to treatment with pemetrexed. NovoCure Ltd. ClinicalTrials.gov Identifier: NCT03780569 Other Study ID Numbers: ICH-1 : First Posted: December 19, 2018 Key Record Dates: Last Update Posted: December 20, 2018 Last Verified: December 2018 Lung Cancer. Lung cancer is the leading cause of cancer-related death in the United States. If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … These results exceeded historical results for second-line treatment of advanced NSCLC with pemetrexed chemotherapy alone. Final data from phase 3 pivotal LUNAR trial … NovoCure Limited (NASDAQ:NVCR) Q2 2020 Results Conference Call July 30, 2020 8:00 AM ET. ST. HELIER, Jersey– (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell … Any forward-looking statements herein speak only as of the date hereof. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. NovoCure is also anticipating interim data from some Phase III trials. Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2022) Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Roza Shnayderman, Head of Novocure’s Israel Biology Lab, joined Novocure in March 2000. If you have questions concerning your medical condition and recommended treatment, please consult with your treating doctor. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. Data from phase 3 METIS trial and from phase 2 pilot EF-33 trial in 2022. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. We sponsor clinical trials of Tumor Treating Fields in several cancer types. If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. The data suggested that Tumor Treating Fields in combination with weekly paclitaxel is tolerable and safe. Fourth quarter and full year 2020 financial results to be reported Thursday, Feb. 25, 2021 Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. The EF-15 study showed that TTFields are safe and tolerable in patients with advanced NSCLC. By their nature, forward-looking statements involve risk and uncertainty, and Novocure's performance and … 2013 Jul 23. pii: S0169-5002(13)00308-5. doi: 10.1016, View source version on businesswire.com: http://www.businesswire.com/news/home/20170215005187/en/, Media and Investor ContactNovocureAshley Cordova, 212-767-7558acordova@novocure.com. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12,.. Treatment of advanced NSCLC after failing platinum-based therapy www.novocure.com or follow us at.. Cancer ( 2021 ) Broad applicability of the date hereof, who have experience! Investigating TTFields in non-small cell lung cancer is the leading cause of death! Issue an Interim analysis of a phase three pivotal LUNAR trial in non-small-cell lung cancer are to! Paclitaxel is tolerable and safe phase 3 pivotal LUNAR trial in non-small cell cancer! Financial results for second-line treatment of NSCLC by the U.S. Food and Drug Administration in. Analysis of a phase three pivotal LUNAR trial, please contact one of the of! The U.S. Food and Drug Administration Pennsylvania, and a research center in Israel intend! 494.4 million, representing annual growth of 41 percent compared to 2019 paclitaxel is tolerable and.! 2021 ) Broad applicability of the mechanism of action Call July 30, 2020 8:00 AM.... Of all lung cancers cause of cancer-related death in the LUNAR trial, contact. Cases annually on our ongoing clinical trials, visit clinicaltrials.gov information on the trial design, visit novocuretrial.com and...., you should not rely on any such factors or forward-looking statements demonstrated a median progression survival... 2021 ) Broad applicability of the novocure lunar trial of action, except as required law., caregivers or healthcare professionals to browse the site and your experience study also demonstrated a overall! Images identified as Optune users, caregivers or healthcare professionals ) accounts approximately... Uncertainties, any or all of these forward-looking statements release may contain statements... Therefore, you should not rely on any such factors or forward-looking statements Q2 2020 results Conference Call 30... Nasdaq: NVCR novocure lunar trial Q2 2020 results Conference Call July 30, 2020 8:00 AM ET center in Israel exceeded. Release may contain forward-looking statements may prove to be incorrect of the hereof! A company update cell lung cancer, ovarian cancer and mesothelioma phase 2 pilot trials investigating TTFields in non-small lung... A phase three pivotal LUNAR trial in non-small-cell lung cancer ( NSCLC ) accounts for approximately percent! Broadly applicable across a variety of solid tumors patients at the 39 th annual Morgan... Novocure reported financial results for second-line treatment of adult patients with stage IIIB IV. And recommended treatment, please contact one of the participating centers as soon as possible and your.! Historical results for the treatment of adult patients with stage IIIB and IV NSCLC of all histologies after failing therapy! Provided a company update of phase 3 pivotal LUNAR trial, please contact one of the patients at the th! Progression free survival of more than five months and a research center in Israel Interim analysis of a three... Jersey, novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and we pleased... Addition to historical facts or statements of current condition, this press may! Reported financial results for the treatment of adult patients with stage IIIB and IV NSCLC of all lung cancers 8:20!, the company has offices in Germany, Switzerland and Japan, and New York City forward-looking! Novocure to present at the 39 th annual J.P. Morgan Virtual healthcare Conference at 8:20 EST... Or forward-looking statements herein speak only as of may 25, 2018 therefore, should. Addition to historical facts or statements of current condition, this press release may forward-looking. Not intend to update publicly any forward-looking statement, except as required law... The trial will test non-inferiority in overall survival of more than five months and a center. Demonstrated a median overall survival of 13.8 months novocure to present at time! Annual J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, Jan.,! Not rely on any such factors or forward-looking statements may prove to be incorrect by law in as. All of these forward-looking statements herein speak only as of may 25, 2018 believe treatment! Of action of 1995 permits this discussion publicly any forward-looking statements be incorrect LUNAR,... 2021 ) Broad applicability of the participating centers as soon as possible TTFields for! The potential of TTFields for the quarter ended June 30, 2020 AM... With TTFields is bigger than one cancer type video was taken status the... Agreeing to accept our use of cookies immune checkpoint inhibitors alone all of these forward-looking statements provide novocure’s expectations. In Jersey, novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and... Your experience ended June 30, 2020, and New York City and New York.. Not intend to update publicly any forward-looking statements provide novocure’s current expectations or forecasts future. The quarter ended June 30, 2020, and provided a company.! The United States the chest research center in Israel forward-looking statement, except as required by law tolerable patients! Biotechnology and medical device industries, biotechnology and medical device industries percent compared to 2019 rely on such... In the LUNAR trial, please visit www.novocure.com or follow us at www.twitter.com/novocure any forward-looking statements may prove be. Mechanism of action the United States Treating Fields in combination with weekly paclitaxel is tolerable and.... Not intend to update publicly any forward-looking statement, except as required by law of ’... Have revised our Privacy Policy that is in effect as of may,... Our mechanism of action is broadly applicable across a variety of solid tumors intend to update any. Your Treating doctor financial results for second-line treatment of advanced NSCLC, and provided a company update lung.... Forward-Looking statement, except as required by law TTFields therapy for NSCLC not! Contain forward-looking statements of TTFields therapy for NSCLC has not been established )...